trending Market Intelligence /marketintelligence/en/news-insights/trending/hcffqoipqb2yxmurzdectg2 content esgSubNav
In This List

Fennec's ear damage prevention drug gets US FDA fast track status

Blog

Post-webinar Q&A: Global Credit Risk Trends 2021 and Beyond

Blog

University Essentials: From Crisis to Resilience – Navigating Sustainable Recovery

Blog

EV impact; vaccines to boost job market; coal supply constraints

Blog

Shore Capital is Now Available in S&P Global’s Aftermarket Research Collection


Fennec's ear damage prevention drug gets US FDA fast track status

The U.S. Food and Drug Administration granted the fast-track designation to Fennec Pharmaceuticals Inc.'s Pedmark to prevent ototoxicity, or ear damage, as a side-effect of cisplatin chemotherapy in children with standard-risk hepatoblastoma.

Hepatoblastoma is a very rare cancerous tumor that starts in the liver and primarily affects children.

The fast track designation allows the FDA to accelerate the review process for drugs indicated to treat serious and life-threatening conditions.